Top Markets
#1 Akedo Akedo +63.85%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.67%
#4 Cross Cross +44.24%
#5 Black Phoenix Black Phoenix +34.14%
#6 Velvet Velvet +29.70%
#7 OVERTAKE OVERTAKE +26.36%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.57%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.55%
#10 Palladium Network Palladium Network +12.47%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
OncoCyte Corporation OncoCyte Corporation

OncoCyte Corporation

OCX
Rank in Stocks #38927
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes,... OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
Share Price
$2.84
Last synced: 2025-07-14
Market Cap
$729.71K
Change (1 day)
-0.70%
Change (1 year)
0.00%
Country
US
Trade OncoCyte Corporation (OCX)

Category

Healthcare
Operating Margin for OncoCyte Corporation (OCX)
Operating Margin as of 2026 TTM: 0.00%
According to OncoCyte Corporation latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for OncoCyte Corporation from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.